JMP Securities Upgrades Allergen (AGN) to Market Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Allergen (AGN) Revenue Growth Plans Might Be Overly Ambitious
February 6, 2013 1:27 PM ESTJefferies today maintained a Hold rating on Allergen (NYSE: AGN) and raised its price target to $100.00 (from $95.00). Yesterday Allergan reported Q4 EPS of $1.15, $0.05 worse than the analyst estimate of $1.20. Adjusted for an R&D tax credit that got delayed until January, EPS would have been $1.21. Allergen... More
Allergan, Inc. (AGN) Misses Q4 EPS by 5c; Issues Mixed FY13 Outlook
February 5, 2013 9:02 AM ESTAllergan, Inc. (NYSE: AGN) reported Q4 EPS of $1.15, $0.05 worse than the analyst estimate of $1.20. Revenue for the quarter came in at $1.48 million versus the consensus estimate of $1.51 million.
Allergan, Inc. sees FY2013 EPS of $4.75-4.83, versus the consensus of $4.74. Allergan, Inc. sees FY2013... More
